COMMUNIQUÉS West-GlobeNewswire

From Genetic Puzzle to Industrial Platform
08/04/2026
Kraig’s Breakthrough Moment Could Redefining Advanced Materials DENVER, April 08, 2026 (GLOBE NEWSWIRE) -- ( www.247marketnews.com ) - For years, the promise of spider silk has lived at the intersection of science [...]
Ritedose Announces Manufacturing for Tenpoint Therapeutics’ Presbyopia Eye Drop
08/04/2026
Partnership Signals Commercial Readiness and Manufacturing Strength for Groundbreaking Ophthalmic Treatment COLUMBIA, S.C., April 08, 2026 (GLOBE NEWSWIRE) -- The Ritedose Corporation, Inc. (Ritedose), the largest [...]
ProQR Announces Partnership with Ginkgo Bioworks and Formation of AI Advisory Board
08/04/2026
ProQR and Ginkgo Bioworks to collaborate on autonomous lab high throughput data generation to support ProQR’s AI-enabled drug discovery for Axiomer™ ProQR establishes AI Advisory Board with leaders from industry and [...]
Spectral AI Names David McGuire, CPA, as Chief Financial Officer
08/04/2026
DALLAS, April 08, 2026 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”) , an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate [...]
UroGen Launches LG-UTUC Luminaries Initiative Recognizing Excellence and Leadership in Treatment of Patients with Low-Grade Upper Tract Urothelial Cancer
08/04/2026
PRINCETON, N.J., April 08, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, [...]
ANI Pharmaceuticals Announces FDA Approval and Launch of Isosorbide Mononitrate Tablet
08/04/2026
PRINCETON, N.J., April 08, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that following final approval from the U.S. Food and Drug Administration (FDA) for its [...]
Nurix Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update
08/04/2026
Enrolling Phase 2 DAYBreak CLL-201 bexobrutideg trial designed to support Accelerated Approval in relapsed/refractory chronic lymphocytic leukemia (r/r CLL) Enabling Phase 3 DAYBreak CLL-306 bexobrutideg confirmatory [...]
Zelluna ASA – Disclosure of voting rights of Annual General Meeting
08/04/2026
Oslo, April 8, 2026: In connection with the Annual General Meeting of Zelluna ASA to be held on April 23, 2026, Anders Tuv, Chair of the Board of Directors, has, as of the date of this announcement, received proxy-based [...]
Clariane annonce l’offre de 500 millions d’euros d’obligations senior en vue de refinancer une partie de son endettement existant
08/04/2026
NE PAS DIFFUSER, PUBLIER OU DISTRIBUER, DIRECTEMENT OU INDIRECTEMENT, AUX ÉTATS-UNIS D’AMÉRIQUE, AU CANADA, AU JAPON OU EN AUSTRALIE, OU DANS TOUTE AUTRE JURIDICTION OU IL EST ILLÉGAL DE DIFFUSER, DE PUBLIER OU DE [...]
Clariane has launched a proposed offering of €500 million of senior notes to refinance part of its existing indebtedness
08/04/2026
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, JAPAN OR AUSTRALIA OR ANY OTHER JURISDICTION IN WHICH IT WOULD BE UNLAWFUL TO DO SO Clariane has [...]
AtaiBeckley’s BPL-003 Shows Rapid, Durable Antidepressant Response in Treatment-Resistant Depression Patients on SSRIs; Phase 2a Data Published in CNS Drugs
08/04/2026
66.7% of participants achieved an antidepressant response by Day 2 following a single intranasal dose of BPL-003 in both the 10 mg (n=6) and 12 mg (n=6) cohorts Durable responses observed at Day 85: 83% (5/6) (10 mg) [...]
Novonesis expands global footprint with acquisition of production facility in Southeast Asia
08/04/2026
Novonesis expands global footprint with acquisition of production facility in Southeast Asia Investment of around USD 50 million strengthens fermentation capabilities and supports the company’s long-term growth [...]
Aravax Strengthens Board with Appointments of Carsten Hellmann and Andrew Oxtoby
08/04/2026
MELBOURNE, Australia and OXFORD, United Kingdom, April 08, 2026 (GLOBE NEWSWIRE) -- Aravax, a clinical-stage biotechnology company developing next-generation, disease-modifying immunotherapies for food allergy, today [...]
Fortrea dévoile Fortrea Intelligent Technology™ : une technologie destinée à permettre aux investigateurs et aux centres d’essais cliniques de mener des essais plus intelligents et mieux intégrés
08/04/2026
Cette offre de solutions optimisée par l’IA s’appuie sur une technologie innovante et perfectionnée visant à renforcer l’efficacité, la fiabilité et la qualité Points clés : Une solution conçue pour révolutionner les [...]
Mesoblast Receives IND Clearance from FDA to Directly Proceed to Registrational Trial for Approval of Ryoncil® in Duchenne Muscular Dystrophy
08/04/2026
Partnering with Parent Project Muscular Dystrophy to ensure timely access to the trial for eligible patients ~15,000 children are living with DMD in the U.S. NEW YORK, April 07, 2026 (GLOBE NEWSWIRE) -- Mesoblast [...]
DERMAdoctor Announces Initiative to Broaden Public Access to Dermatologist-Developed Clinical Skincare
08/04/2026
Davie, FL, April 08, 2026 (GLOBE NEWSWIRE) -- DERMAdoctor , the clinical skincare company founded by board-certified dermatologist Dr. Audrey Kunin, announced today that it is undertaking a renewed initiative designed [...]
Leanzene Claims Evaluated: The Leading Keto BHB + ACV Weight Loss Gummy Brand on the Market
08/04/2026
A 2026 informational consumer evaluation of Leanzene's keto BHB gummy and apple cider vinegar weight loss formula, ingredient research context, proprietary blend label transparency, and what men and women should verify [...]
Jelly Lean Gummies Under Investigation: Evaluating the Homemade Jelly Burn Gelatin Trick Recipe Formulation Claims (Avoid Scam Risks)
08/04/2026
A 2026 informational overview providing context on increased search activity around JellyLean gummies, the homemade gelatin trick recipe trend, jelly burn weight loss hack variations, whether JellyLean is legit, full [...]
COSCIENS Comments on Unusual Market Activity
07/04/2026
TORONTO, ONTARIO, April 07, 2026 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (TSX: CSCI) (OTCQB: CSCIF) (“ COSCIENS ” or the “ Company ”) is issuing this news release in response to unusual market activity. While the [...]

Pages